CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo

Cancer Immunology, Immunotherapy

Volumn 64, Issue 2, 2015, Pages 225-235

  Wennerberg, Erik ^a   Kremer, Veronika ^a   Childs, Richard ^b   Lundqvist, Andreas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Adoptive cell therapy; CXCL10; CXCR3; Migration; Natural killer cells

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; DOXORUBICIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; ALPHA CHEMOKINE; ANTINEOPLASTIC ANTIBIOTIC;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CELL EXPANSION; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; LOW DRUG DOSE; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; METABOLISM; MORTALITY; NEOPLASMS; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CXCL10; CHEMOKINES, CXC; CHEMOTAXIS, LEUKOCYTE; DISEASE MODELS, ANIMAL; DOXORUBICIN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; RECEPTORS, CXCR3; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925502725     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1629-5     Document Type: Article

References (53)

1. Sarhan D, D’Arcy P, Wennerberg E, Liden M, Hu J, Winqvist O, Rolny C, Lundqvist A (2013) Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-gamma. Eur J Immunol 43(1):249–257. doi:10.1002/eji.201242735
2. Benson DM Jr, Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, Hofmeister CC, Efebera Y, Andre P, Romagne F, Blery M, Bonnafous C, Zhang J, Clever D, Caligiuri MA, Farag SS (2011) IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 118(24):6387–6391. doi:10.1182/blood-2011-06-360255
3. Salagianni M, Lekka E, Moustaki A, Iliopoulou EG, Baxevanis CN, Papamichail M, Perez SA (2011) NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. J Immunol 186(6):3327–3335. doi:10.4049/jimmunol.1000652
4. Kim EK, Ahn YO, Kim S, Kim TM, Keam B, Heo DS (2013) Ex vivo activation and expansion of natural killer cells from patients with advanced cancer with feeder cells from healthy volunteers. Cytotherapy 15(2):231–241.e1. doi:10.1016/j.jcyt.2012.10.019
5. Berg M, Lundqvist A, McCoy P Jr, Samsel L, Fan Y, Tawab A, Childs R (2009) Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 11(3):341–355. doi:10.1080/14653240902807034
6. Imai C, Iwamoto S, Campana D (2005) Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106(1):376–383. doi:10.1182/blood-2004-12-4797
7. Takanami I, Takeuchi K, Giga M (2001) The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Surg 121(6):1058–1063. doi:10.1067/mtc.2001.113026
8. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Hokita S, Aikou T (2000) Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88(3):577–583
9. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, Zuil M, Callol L (2002) Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35(1):23–28
10. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M (1997) The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79(12):2320–2328
11. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562):2097–2100. doi:10.1126/science.1068440
12. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105(8):3051–3057. doi:10.1182/blood-2004-07-2974
13. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA (2011) Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 17(19):6287–6297. doi:10.1158/1078-0432.CCR-11-1347
14. Curti A, Ruggeri L, D’Addio A, Bontadini A, Dan E, Motta MR, Trabanelli S, Giudice V, Urbani E, Martinelli G, Paolini S, Fruet F, Isidori A, Parisi S, Bandini G, Baccarani M, Velardi A, Lemoli RM (2011) Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118(12):3273–3279. doi:10.1182/blood-2011-01-329508
15. Lundqvist A, Berg M, Smith A, Childs RW (2011) Bortezomib treatment to potentiate the anti-tumor immunity of ex vivo expanded adoptively infused autologous natural killer cells. J Cancer 2:383–385
16. Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, Mori L, Cosman D, De Libero G, Wodnar-Filipowicz A (2005) Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 105(9):3615–3622. doi:10.1182/blood-2004-07-2585
17. Sanchez-Correa B, Morgado S, Gayoso I, Bergua JM, Casado JG, Arcos MJ, Bengochea ML, Duran E, Solana R, Tarazona R (2011) Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother 60(8):1195–1205. doi:10.1007/s00262-011-1050-2
18. Yang Q, Hokland ME, Bryant JL, Zhang Y, Nannmark U, Watkins SC, Goldfarb RH, Herberman RB, Basse PH (2003) Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases. Int J Cancer 105(4):512–519. doi:10.1002/ijc.11119
19. Hagenaars M, Zwaveling S, Kuppen PJ, Ensink NG, Eggermont AM, Hokland ME, Basse PH, van de Velde CJ, Fleuren GJ, Nannmark U (1998) Characteristics of tumor infiltration by adoptively transferred and endogenous natural-killer cells in a syngeneic rat model: implications for the mechanism behind anti-tumor responses. Int J Cancer 78(6):783–789
20. Fisher B, Packard BS, Read EJ, Carrasquillo JA, Carter CS, Topalian SL, Yang JC, Yolles P, Larson SM, Rosenberg SA (1989) Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 7(2):250–261
21. Maghazachi AA (2010) Role of chemokines in the biology of natural killer cells. Curr Top Microbiol Immunol 341:37–58. doi:10.1007/82_2010_20
22. Groom JR, Luster AD (2011) CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 89(2):207–215. doi:10.1038/icb.2010.158
23. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A (1998) Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 187(6):875–883
24. Somanchi SS, Somanchi A, Cooper LJ, Lee DA (2012) Engineering lymph node homing of ex vivo expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood 119(22):5164–5172. doi:10.1182/blood-2011-11-389924
25. Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, Whittington M, Yang Y, Overwijk WW, Lizee G, Hwu P (2010) Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res 16(22):5458–5468. doi:10.1158/1078-0432.CCR-10-0712
26. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH, Pages F, Trajanoski Z, Galon J (2010) Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 138(4):1429–1440. doi:10.1053/j.gastro.2009.10.057
27. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F, Galon J (2011) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29(6):610–618. doi:10.1200/JCO.2010.30.5425
28. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27(35):5944–5951. doi:10.1200/JCO.2008.19.6147
29. Luster AD, Unkeless JC, Ravetch JV (1985) Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315(6021):672–676
30. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF (2009) Chemokine expression in melanoma metastases associated with CD8 + T-cell recruitment. Cancer Res 69(7):3077–3085. doi:10.1158/0008-5472.CAN-08-2281
31. Kondo T, Nakazawa H, Ito F, Hashimoto Y, Osaka Y, Futatsuyama K, Toma H, Tanabe K (2006) Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 97(8):780–786. doi:10.1111/j.1349-7006.2006.00231.x
32. Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, Witz IP, Ben-Baruch A (2007) CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 67(7):3396–3405. doi:10.1158/0008-5472.CAN-06-3087
33. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964. doi:10.1126/science.1129139
34. Metelitsa LS, Wu HW, Wang H, Yang Y, Warsi Z, Asgharzadeh S, Groshen S, Wilson SB, Seeger RC (2004) Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med 199(9):1213–1221. doi:10.1084/jem.20031462
35. Adler EP, Lemken CA, Katchen NS, Kurt RA (2003) A dual role for tumor-derived chemokine RANTES (CCL5). Immunol Lett 90(2–3):187–194
36. Erreni M, Bianchi P, Laghi L, Mirolo M, Fabbri M, Locati M, Mantovani A, Allavena P (2009) Expression of chemokines and chemokine receptors in human colon cancer. Methods Enzymol 460:105–121. doi:10.1016/S0076-6879(09)05205-7
37. Inngjerdingen M, Damaj B, Maghazachi AA (2001) Expression and regulation of chemokine receptors in human natural killer cells. Blood 97(2):367–375
38. Hodge DL, Schill WB, Wang JM, Blanca I, Reynolds DA, Ortaldo JR, Young HA (2002) IL-2 and IL-12 alter NK cell responsiveness to IFN-gamma-inducible protein 10 by down-regulating CXCR3 expression. J Immunol 168(12):6090–6098
39. Hanna J, Wald O, Goldman-Wohl D, Prus D, Markel G, Gazit R, Katz G, Haimov-Kochman R, Fujii N, Yagel S, Peled A, Mandelboim O (2003) CXCL12 expression by invasive trophoblasts induces the specific migration of CD16-human natural killer cells. Blood 102(5):1569–1577. doi:10.1182/blood-2003-02-0517
40. Beider K, Nagler A, Wald O, Franitza S, Dagan-Berger M, Wald H, Giladi H, Brocke S, Hanna J, Mandelboim O, Darash-Yahana M, Galun E, Peled A (2003) Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood 102(6):1951–1958. doi:10.1182/blood-2002-10-3293
41. Evans JH, Horowitz A, Mehrabi M, Wise EL, Pease JE, Riley EM, Davis DM (2011) A distinct subset of human NK cells expressing HLA-DR expand in response to IL-2 and can aid immune responses to BCG. Eur J Immunol 41(7):1924–1933. doi:10.1002/eji.201041180
42. Kajitani K, Tanaka Y, Arihiro K, Kataoka T, Ohdan H (2012) Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells. Breast Cancer Res Treat 134(1):139–155. doi:10.1007/s10549-011-1944-x
43. Lim O, Lee Y, Chung H, Her JH, Kang SM, Jung MY, Min B, Shin H, Kim TM, Heo DS, Hwang YK, Shin EC (2013) GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo. PLoS ONE 8(1):e53611. doi:10.1371/journal.pone.0053611
44. Sutlu T, Stellan B, Gilljam M, Quezada HC, Nahi H, Gahrton G, Alici E (2010) Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy 12(8):1044–1055. doi:10.3109/14653249.2010.504770
45. Loos T, Dekeyzer L, Struyf S, Schutyser E, Gijsbers K, Gouwy M, Fraeyman A, Put W, Ronsse I, Grillet B, Opdenakker G, Van Damme J, Proost P (2006) TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis. Lab Invest 86(9):902–916. doi:10.1038/labinvest.3700453
46. Furuya M, Suyama T, Usui H, Kasuya Y, Nishiyama M, Tanaka N, Ishiwata I, Nagai Y, Shozu M, Kimura S (2007) Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum Pathol 38(11):1676–1687. doi:10.1016/j.humpath.2007.03.023
47. Muthuswamy R, Berk E, Junecko BF, Zeh HJ, Zureikat AH, Normolle D, Luong TM, Reinhart TA, Bartlett DL, Kalinski P (2012) NF-kappaB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res 72(15):3735–3743. doi:10.1158/0008-5472.CAN-11-4136
48. Wennerberg E, Sarhan D, Carlsten M, Kaminskyy VO, D’Arcy P, Zhivotovsky B, Childs R, Lundqvist A (2013) Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling. Int J Cancer 133(7):1643–1652. doi:10.1002/ijc.28163
49. Wendel M, Galani IE, Suri-Payer E, Cerwenka A (2008) Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 68(20):8437–8445. doi:10.1158/0008-5472.CAN-08-1440
50. Casado JG, Pawelec G, Morgado S, Sanchez-Correa B, Delgado E, Gayoso I, Duran E, Solana R, Tarazona R (2009) Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother 58(9):1517–1526. doi:10.1007/s00262-009-0682-y
51. Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, Umansky V, Paschen A, Sucker A, Pende D, Groh V, Biassoni R, Hoglund P, Kato M, Shibuya K, Schadendorf D, Anichini A, Ferrone S, Velardi A, Karre K, Shibuya A, Carbone E, Colucci F (2009) NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 119(5):1251–1263. doi:10.1172/JCI36022
52. Lee JH, Park S, Cheon S, Lee JH, Kim S, Hur DY, Kim TS, Yoon SR, Yang Y, Bang SI, Park H, Lee HT, Cho D (2011) 1,25-Dihydroxyvitamin D(3) enhances NK susceptibility of human melanoma cells via Hsp60-mediated FAS expression. Eur J Immunol 41(10):2937–2946. doi:10.1002/eji.201141597
53. Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A (2014) Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res 20(15):4096–4106. doi:10.1158/1078-0432.CCR-14-0635